1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key
Industry Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validation
2.7. Assumptions
and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Drug
Type (Rilutek (Riluzole), Edaravone (Radicava))
5.2.2.
By Treatment Type (Physical Therapy,
Speech Therapy, Medication, Respiratory Therapy, Others)
5.2.3.
By End-Users (Hospitals & Clinics,
Research and Academic institutes, others)
5.2.4.
By Region
5.2.5.
By Company (2022)
5.3. Market Map
6.
Asia Pacific Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1.
By Drug Type
6.2.2.
By Treatment Type
6.2.3.
By End-Users
6.2.4.
By Country
6.3. Asia Pacific: Country Analysis
6.3.1.
China Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Type
6.3.1.2.2.
By Treatment Type
6.3.1.2.3.
By End-Users
6.3.2.
India Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Type
6.3.2.2.2.
By Treatment Type
6.3.2.2.3.
By End-Users
6.3.3.
Australia Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Type
6.3.3.2.2.
By Treatment Type
6.3.3.2.3.
By End-Users
6.3.4.
Japan Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Drug Type
6.3.4.2.2.
By Treatment Type
6.3.4.2.3.
By End-Users
6.3.5.
South Korea Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Drug Type
6.3.5.2.2.
By Treatment Type
6.3.5.2.3.
By End-Users
7.
Europe Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Drug Type
7.2.2.
By Treatment Type
7.2.3.
By End-Users
7.2.4.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Type
7.3.1.2.2.
By Treatment Type
7.3.1.2.3.
By End-Users
7.3.2.
Germany Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Type
7.3.2.2.2.
By Treatment Type
7.3.2.2.3.
By End-Users
7.3.3.
Spain Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Type
7.3.3.2.2.
By Treatment Type
7.3.3.2.3.
By End-Users
7.3.4.
Italy Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Drug Type
7.3.4.2.2.
By Treatment Type
7.3.4.2.3.
By End-Users
7.3.5.
United Kingdom Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Drug Type
7.3.5.2.2.
By Treatment Type
7.3.5.2.3.
By End-Users
8.
North America Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Drug Type
8.2.2.
By Treatment Type
8.2.3.
By End-Users
8.2.4.
By Country
8.3. North America: Country Analysis
8.3.1.
United States Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Type
8.3.1.2.2.
By Treatment Type
8.3.1.2.3.
By End-Users
8.3.2.
Mexico Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Type
8.3.2.2.2.
By Treatment Type
8.3.2.2.3.
By End-Users
8.3.3.
Canada Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Type
8.3.3.2.2.
By Treatment Type
8.3.3.2.3.
By End-Users
9.
South America Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Drug Type
9.2.2.
By Treatment Type
9.2.3.
By End-Users
9.2.4.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Type
9.3.1.2.2.
By Treatment Type
9.3.1.2.3.
By End-Users
9.3.2.
Argentina Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Type
9.3.2.2.2.
By Treatment Type
9.3.2.2.3.
By End-Users
9.3.3.
Colombia Amyotrophic
Lateral Sclerosis (ALS) Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Type
9.3.3.2.2.
By Treatment Type
9.3.3.2.3.
By End-Users
10.
Middle East and Africa
Amyotrophic Lateral Sclerosis (ALS) Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Drug Type
10.2.2.
By Treatment Type
10.2.3.
By End-Users
10.2.4. By Country
10.3.
MEA: Country
Analysis
10.3.1. South Africa Amyotrophic Lateral Sclerosis (ALS) Market
Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Drug Type
10.3.1.2.2.
By Treatment Type
10.3.1.2.3.
By End-Users
10.3.2. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market
Outlook
10.3.2.1. Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Drug Type
10.3.2.2.2.
By Treatment Type
10.3.2.2.3.
By End-Users
10.3.3. UAE Amyotrophic Lateral Sclerosis (ALS) Market Outlook
10.3.3.1. Market Size &
Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Drug Type
10.3.3.2.2.
By Treatment Type
10.3.3.2.3.
By End-Users
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers &
Acquisitions
13. Global Amyotrophic Lateral Sclerosis (ALS) Market: SWOT
Analysis
14.
Porter’s Five Forces
Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New
Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Product
15. PESTLE Analysis
16. Competitive Landscape
16.1.
Sanofi S.A
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Brainstorm Cell Therapeutics Inc.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Biogen Inc.
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4.
Bausch Health Cos
Inc.
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5.
F Hoffmann-la Roche Ltd
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6.
Ionis Pharmaceuticals Inc.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7.
Mylan Pharma Inc.
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8.
Sun Pharmaceutical Industries Inc
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9.
Orion Pharma A/S
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.AB Science SA
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17.
Strategic Recommendations
18.
About Us &
Disclaimer